BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Law MF, Ho R, Cheung CK, Tam LH, Ma K, So KC, Ip B, So J, Lai J, Ng J, Tam TH. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016; 22(28): 6484-6500 [PMID: 27605883 DOI: 10.3748/wjg.v22.i28.6484]
URL: https://www.wjgnet.com/1007-9327/full/v22/i28/6484.htm
Number Citing Articles
1
Marco Picardi, Roberta Della Pepa, Claudia Giordano, Irene Zacheo, Novella Pugliese, Chiara Mortaruolo, Fabio Trastulli, Antonio Giordano, Mariano Lucignano, Maria Di Perna, Marta Raimondo, Claudia Salvatore, Fabrizio Pane. Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCLBlood 2019; 133(5): 498 doi: 10.1182/blood-2018-10-878892
2
Jeffrey J. Bruno, Frank P. Tverdek. Oncologic Critical Care2019; : 1 doi: 10.1007/978-3-319-74698-2_27-1
3
Michee M Bazie, Mahamoudou Sanou, Florencia Wendkuuni Djigma, Tegwinde Rebeca Compaore, Dorcas Obiri-Yeboah, Benoît Kabamba, Bolni Marius Nagalo, Jacques Simpore, Rasmata Ouédraogo. Genetic diversity and occult hepatitis B infection in Africa: A comprehensive reviewWorld Journal of Hepatology 2024; 16(5): 843-859 doi: 10.4254/wjh.v16.i5.843
4
Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, Sakurako Ito, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Tomohisa Nomura, Manabu Sugita. Current perspectives of viral hepatitisWorld Journal of Gastroenterology 2024; 30(18): 2402-2417 doi: 10.3748/wjg.v30.i18.2402
5
Murali Janakiram, Sakshi Jasra, David Aboulafia. Effect of Hepatitis B and C Infection on Recruitment for Cancer Clinical TrialsJournal of Clinical Oncology 2018; 36(10): 1047 doi: 10.1200/JCO.2017.76.9307
6
Nobuhiko Yamauchi, Dai Maruyama, Ilseung Choi, Yoshiko Atsuta, Rika Sakai, Kazuho Miyashita, Yukiyoshi Moriuchi, Hideki Tsujimura, Nobuko Kubota, Go Yamamoto, Tadahiko Igarashi, Koji Izutsu, Shinichiro Yoshida, Kensuke Kojima, Toshiki Uchida, Yoshiko Inoue, Norifumi Tsukamoto, Eiichi Ohtsuka, Sachiko Suzuki, Yoko Inaguma, Satoshi Ichikawa, Hiroshi Gomyo, Yoko Ushijima, Kisato Nosaka, Mio Kurata, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami, Shigeru Kusumoto. Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapyCancer Science 2021; 112(5): 1943 doi: 10.1111/cas.14846
7
Tianxiang Lei, Fengbo Tan, Zhouhua Hou, Peng Liu, Xianhui Zhao, Heli Liu. Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With ImatinibFrontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.596500
8
Natalia Kreiniz, Ofrat Beyar Katz, Aaron Polliack, Tamar Tadmor. The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic LeukemiaClinical Lymphoma Myeloma and Leukemia 2017; 17(12): 863 doi: 10.1016/j.clml.2017.07.008
9
Cara D. Varley, Kevin L. Winthrop. Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)Current Rheumatology Reports 2021; 23(9) doi: 10.1007/s11926-021-01037-3
10
Jian Li, Ming Wang, Bo Zhang, Xin Wu, Tian-Long Lin, Xiu-Feng Liu, Ye Zhou, Xin-Hua Zhang, Hao Xu, Li-Jing Shen, Jing Zou, Ping Lu, Dong Zhang, Wei-Jun Gu, Mei-Xia Zhang, Jian Pan, Hui Cao, Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumorsWorld Journal of Gastroenterology 2018; 24(46): 5189-5202 doi: 10.3748/wjg.v24.i46.5189
11
Carmen Ka Man Cheung, Man Fai Law, David Chun Chao, Sunny Hei Wong, Rita Ho, Amelia Chien Wei Chao, Jennifer Wing Yan Lai, Ted Yun Tat Chan, Mark Tsz Kin Tam, Sam Lik Fung Lau, Tommy Ho Chi Tam. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta‐analysisJournal of Digestive Diseases 2020; 21(3): 160 doi: 10.1111/1751-2980.12848
12
Ling-Yi Wang, Sung-Chao Chu, Yin Lo, Yen-Yun Yang, K. Arnold Chan. Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in TaiwanJAMA Network Open 2021; 4(4): e214132 doi: 10.1001/jamanetworkopen.2021.4132
13
Esma EROĞLU, Cahit YAVUZ. Seroprevalence of HBsAg, Anti-HBs, Anti-HCV and Anti-HIV in Behçet’s DiseaseJournal of Contemporary Medicine 2021; 11(5): 690 doi: 10.16899/jcm.912691
14
Wei Huang, Lingyao Du, Hong Tang. Hepatitis B Virus Reactivation: Overview and ManagementFuture Virology 2021; 16(12): 821 doi: 10.2217/fvl-2021-0275
15
Bansi P Savaliya, Ramin Shekouhi, Fatima Mubarak, Harsheen K Manaise, Paola Berrios Jimenez, Gabrielle Kowkabany, Reed A Popp, Kyle Popp, Emmanuel Gabriel. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitorsWorld Journal of Gastroenterology 2024; 30(24): 3052-3058 doi: 10.3748/wjg.v30.i24.3052
16
Michelle Spaan, Matthew Bruce, Kosh Agarwal, Ivana Carey. The Role of Anti-HBs in Hepatitis B Reactivation during Direct-Acting Antiviral Therapy for Chronic Hepatitis CAntiviral Therapy 2018; 23(6): 539 doi: 10.3851/IMP3259
17
Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole, Lisa I. Backus. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antiviralsHepatology 2017; 66(1): 27 doi: 10.1002/hep.29135
18
Lars Kurch, Thomas W. Georgi, Astrid Monecke, Daniel Seehofer, Gudrun Borte, Osama Sabri, Regine Kluge, Simone Heyn, Matthias Pierer, Uwe Platzbecker, Sabine Kayser. Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case ReportFrontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.798757
19
Jeffrey J. Bruno, Frank P. Tverdek. Oncologic Critical Care2020; : 153 doi: 10.1007/978-3-319-74588-6_27
20
Ilkay Bozkurt, Hatun Ozturk Cerik, Seher Kir, Muge Ustaoglu, Mehmet Turgut, Saban Esen. Evaluation of Hepatitis B screening and reactivation in patients receiving rituximab containing chemotherapy: A single‐centre studyInternational Journal of Clinical Practice 2021; 75(10) doi: 10.1111/ijcp.14685
21
Jie Wang, Junqiao Jia, Ran Chen, Shanlong Ding, Qiang Xu, Ting Zhang, Xiangmei Chen, Shuang Liu, Fengmin Lu. RFX1 participates in doxorubicin‐induced hepatitis B virus reactivationCancer Medicine 2018; 7(5): 2021 doi: 10.1002/cam4.1468
22
Alyson Kaplan, Elliott DeHaan, Charles Maltz. Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency VirusACG Case Reports Journal 2021; 8(5): e00594 doi: 10.14309/crj.0000000000000594
23
Jeffrey J. Bruno, Frank P. Tverdek. Oncologic Critical Care2019; : 1 doi: 10.1007/978-3-319-74698-2_27-2
24
Małgorzata Pawłowska, Robert Flisiak, Lidia Gil, Andrzej Horban, Iwona Hus, Jerzy Jaroszewicz, Ewa Lech-Marańda, Jan Styczyński. Profilaktyka reaktywacji zakażeń HBV – rekomendacje grupy roboczej profilaktyki reaktywacji HBVActa Haematologica Polonica 2019; 50(4): 192 doi: 10.2478/ahp-2019-0031
25
Sirish Sanaka, Hans L Tillmann. Article Commentary: Hindsight is 20/20 – the Importance of Knowing! Know your Patients’ HBV StatusAntiviral Therapy 2018; 23(6): 471 doi: 10.3851/IMP3260
26
Prowpanga Udompap, W. Ray Kim. Hepatitis B Virus and Liver Disease2021; : 427 doi: 10.1007/978-981-16-3615-8_18
27
Stefano Molica, Luciano Levato, Rosanna Mirabelli, Alessanda Tedeschi, Mirella Lentini. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patientsLeukemia & Lymphoma 2018; 59(11): 2734 doi: 10.1080/10428194.2018.1436175
28
Tao Li, Jing Li, Yang Yang, Yilin Han, Dirong Wu, Tao Xiao, Yang Wang, Ting Liu, Yonglong Zhao, Yongjun Li, Zeqin Dai, Xiaozhong Fu. Synthesis, pharmacological evaluation, and mechanistic study of adefovir mixed phosphonate derivatives bearing cholic acid and l-amino acid moieties for the treatment of HBVBioorganic & Medicinal Chemistry 2019; 27(16): 3707 doi: 10.1016/j.bmc.2019.07.012
29
Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung, Man Fai Law. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy eraWorld Journal of Gastroenterology 2023; 29(33): 4942-4961 doi: 10.3748/wjg.v29.i33.4942
30
А.В. Чистякова, Н.И. Стуклов, Г.А. Дудина, П.П. Огурцов, Н.В. Мазурчик, А.В. Пивник. Clinical Significance of Chronic Hepatitis C in HIV-infected Patients with Burkitt LymphomaГематология. Трансфузиология. Восточная Европа 2020; (1): 91 doi: 10.34883/PI.2020.6.1.009
31
Malgorzata McMasters, Barbra M. Blair, Hillard M. Lazarus, Carolyn D. Alonso. Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantationBlood Reviews 2021; 47: 100779 doi: 10.1016/j.blre.2020.100779
32
José Pedro Carda, Lurdes Santos, José Mário Mariz, Pedro Monteiro, Humberto Miguel Gonçalves, João Raposo, Maria Gomes da Silva. Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendationsHematology 2021; 26(1): 785 doi: 10.1080/16078454.2021.1980690
33
Branko Borojevic, Ayushi Chauhan, Scott Patterson. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphomaBMJ Case Reports 2021; 14(7): e243526 doi: 10.1136/bcr-2021-243526
34
Chih-An Shih, Wen-Chi Chen. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapyWorld Journal of Clinical Cases 2021; 9(21): 5769-5781 doi: 10.12998/wjcc.v9.i21.5769
35
Ling‐Yi Wang, Sung‐Chao Chu, I‐Yun Chang, K. Arnold Chan. Sex‐specific incidence of hepatitis B virus flares among Bcr‐Abl tyrosine kinase inhibitor users in TaiwanPharmacoepidemiology and Drug Safety 2023; 32(12): 1368 doi: 10.1002/pds.5667
36
Successful Treatment of HCV/TB co-infected Patient With Sofosbuvir and Daclatasvir: A Case ReportFuture Virology 2018; 13(5): 317 doi: 10.2217/fvl-2017-0141
37
Chi-Yu Chen, Tun-Chieh Chen. Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature reviewMedicine 2024; 103(14): e37653 doi: 10.1097/MD.0000000000037653
38
Laura Ambra Nicolini, Emanuela Zappulo, Claudio Viscoli, Malgorzata Mikulska. Management of chronic viral hepatitis in the hematological patientExpert Review of Anti-infective Therapy 2018; 16(3): 227 doi: 10.1080/14787210.2018.1438264
39
Elżbieta Halina Kłujszo, Dorota Zarębska‐Michaluk, Beata Kręcisz, Anna Witkowska. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infectionDermatologic Therapy 2022; 35(3) doi: 10.1111/dth.15274
40
Alessandra Zannella, Massimo Marignani, Paola Begini. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical ManagementViruses 2019; 11(9): 858 doi: 10.3390/v11090858
41
Maria Gabriela Fernandes Dezan, Lourianne Nascimento Cavalcante, Helma Pinchemel Cotrim, Andre Castro Lyra. Hepatobiliary disease after bone marrow transplantExpert Review of Gastroenterology & Hepatology 2023; 17(2): 129 doi: 10.1080/17474124.2023.2169671
42
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology 2018; 74(9): 1111 doi: 10.1007/s00228-018-2487-4
43
Nina Shah, Jack Aiello, David E Avigan, Jesus G Berdeja, Ivan M Borrello, Ajai Chari, Adam D Cohen, Karthik Ganapathi, Lissa Gray, Damian Green, Amrita Krishnan, Yi Lin, Elisabet Manasanch, Nikhil C Munshi, Ajay K Nooka, Aaron P Rapoport, Eric L Smith, Ravi Vij, Madhav Dhodapkar. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaJournal for ImmunoTherapy of Cancer 2020; 8(2): e000734 doi: 10.1136/jitc-2020-000734
44
Yibo Wu, He Huang, Yi Luo. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell TransplantationFrontiers in Immunology 2021; 11 doi: 10.3389/fimmu.2020.610500
45
Matthew Kelling, Lubomir Sokol, Samir Dalia. Hepatitis B Reactivation in the Treatment of Non-Hodgkin LymphomaCancer Control 2018; 25(1) doi: 10.1177/1073274818767879
46
João Marcello de Araujo-Neto, Gabriela Sousa Guimarães, Flavia Ferreira Fernandes, Marcelo A. Soares. Hepatitis B Surface Antibody (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: Two Prospective StudiesViruses 2022; 14(8): 1780 doi: 10.3390/v14081780
47
Yue Yin, Bao Jiang Liu, Yan Hua Zhang, Xin Ye Qiu. Hepatitis B virus reactivation risk associated with immune checkpoint inhibitors in tumor treatment: a retrospective studyJapanese Journal of Clinical Oncology 2024;  doi: 10.1093/jjco/hyae105
48
Anna Korycka-Wołowiec, Dariusz Wołowiec, Tadeusz Robak. The safety profile of monoclonal antibodies for chronic lymphocytic leukemiaExpert Opinion on Drug Safety 2016; : 1 doi: 10.1080/14740338.2017.1264387
49
Mauro Passucci, Chiara Masucci, Francesca Paoletti, Claudia Ielo, Alessandro Costa, Ida Carmosino, Emilia Scalzulli, Maurizio Martelli, Giuseppe Gentile, Massimo Breccia. Case Report: Infectious prophylaxis in hematological malignanciesFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1163175
50
Soe Thiha Maung, Natee Deepan, Pakanat Decharatanachart, Roongruedee Chaiteerakij. Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy – A systematic review and meta‐analysisAsia-Pacific Journal of Clinical Oncology 2024; 20(3): 335 doi: 10.1111/ajco.14055
51
Joe Sasadeusz, Andrew Grigg, Peter D. Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G. Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G. Gish, Kumar Visvanathan. Screening and Prophylaxis to Prevent Hepatitis B ReactivationClinics in Liver Disease 2019; 23(3): 487 doi: 10.1016/j.cld.2019.04.009
52
Sebahat Cam, Mustafa Asim Yoruk. Alteration in Hepatitis B Serology in Children Receiving ChemotherapyViral Immunology 2020; 33(10): 628 doi: 10.1089/vim.2020.0194
53
Nancy Law, Randy A. Taplitz. How I manage infection risk and prevention in patients with lymphoid cancerBlood 2022; 139(10): 1517 doi: 10.1182/blood.2019003687
54
María Buti, María L. Manzano, Rosa M. Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L. Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, María Yébenes, Rafael Esteban, Vincent Wong. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin studyPLOS ONE 2017; 12(9): e0184550 doi: 10.1371/journal.pone.0184550
55
Daniel Sedhom, Melroy D’Souza, Elizabeth John, Vinod Rustgi. Viral Hepatitis and Acute Liver FailureClinics in Liver Disease 2018; 22(2): 289 doi: 10.1016/j.cld.2018.01.005
56
Adeniyi Abraham Adesola, Matei-Alexandru Cozma, Yong-Feng Chen, Bahadar Singh Srichawla, Mihnea-Alexandru Găman. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinibWorld Journal of Hepatology 2023; 15(11): 1188-1195 doi: 10.4254/wjh.v15.i11.1188
57
Arif Kılçar, Atalay Doğru. Evaluation of Hepatitis Serology Screening Frequency and Viral Reactivation in Patients Followed with Biological Therapy or Cytotoxic ChemotherapySDÜ Tıp Fakültesi Dergisi 2024;  doi: 10.17343/sdutfd.1412752
58
Prowpanga Udompap, W. Ray Kim. Hepatitis B Virus and Liver Disease2018; : 315 doi: 10.1007/978-981-10-4843-2_16
59
Anjula Kumari, Shakuntala Shakuntala, Prakash Jha. A DESCRIPTIVE STUDY TO ASSESS THE KNOWLEDGE AND ATTITUDE OF STAFF NURSES REGARDING PREVENTION OF HEPATITIS –BGLOBAL JOURNAL FOR RESEARCH ANALYSIS 2022; : 153 doi: 10.36106/gjra/9009072
60
Kazuo Notsumata, Yoshimoto Nomura, Akihiro Tanaka, Yoshikatsu Nomura, Teruyuki Ueda, Taku Sanada, Hiroyuki Watanabe, Daisyu Toya. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort StudyInternal Medicine 2020; 59(20): 2457 doi: 10.2169/internalmedicine.4445-20
61
Chiara Coluccio, Paola Begini, Alfredo Marzano, Adriano Pellicelli, Barbara Imperatrice, Giulia Anania, Gianfranco Delle Fave, Massimo Marignani. Hepatitis B in patients with hematological diseases: An updateWorld Journal of Hepatology 2017; 9(25): 1043-1053 doi: 10.4254/wjh.v9.i25.1043
62
Ayşe İnci, Özgür Açıkgöz, Mustafa Uygar Kalaycı, Volkan Ülker. The Positivity Ratios of HBsAg, Anti-HBs and Isolated Anti-HBc in Patients with Breast and Gynecologic Cancers Prior to ChemotherapyJournal of Clinical and Experimental Investigations 2018; 9(2) doi: 10.5799/jcei.433817
63
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy eraExpert Review of Anti-infective Therapy 2018; 16(10): 781 doi: 10.1080/14787210.2018.1521270
64
Takako Inoue, Takeshi Matsui, Yasuhito Tanaka. Novel strategies for the early diagnosis of hepatitis B virus reactivationHepatology Research 2021; 51(10): 1033 doi: 10.1111/hepr.13699